Dr. Lang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave A80
Cleveland, OH 44195Phone+1 216-636-2843
Summary
- Julie Lang, MD, is a General Surgeon located in Cleveland, OH, with sub-specialties in Breast and Surgical Oncology. She received her surgical residency at the University of California (San Francisco) and completed her fellowship in Breast Surgical Oncology at the University of Texas M D Anderson Cancer Center. She has significant experience in breast cancer, inflammatory breast cancer, male breast cancer, breast biopsy, and lymph node dissection. Currently, Dr. Lang is Professor of Surgery at the Cleveland Clinic Lerner School of Medicine after holding positions at Keck School of Medicine and University of Arizona College of Medicine. She has several publications to her name and has received several honors/awards, such as Top Doctor, Breast Surgery from Los Angeles Magazine in 2020.
Education & Training
- University of Texas M D Anderson Cancer CenterFellowship, Breast Surgical Oncology, 2006 - 2007
- University of California (San Francisco)Residency, Surgery, 1999 - 2006
- University of North Carolina at Chapel Hill School of MedicineClass of 1999
Certifications & Licensure
- CA State Medical License 2001 - 2026
- OH State Medical License 2020 - 2026
- AZ State Medical License 2007 - 2025
- TX State Medical License 2006 - 2008
- American Board of Surgery Surgery
Awards, Honors, & Recognition
- Top Doctor, Breast Surgery Los Angeles Magazine, 2020
- Top Doctors 2013, Breast Oncology Pasadena Magazine
- Fellow (FACS) American College of Surgeons
Clinical Trials
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
- Study of Topical SOR007 Ointment for Cutaneous Metastases Start of enrollment: 2018 Jan 31
- Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System Start of enrollment: 2018 Mar 29
Publications & Presentations
PubMed
- 139 citationsGenetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy.Xiaojing Shi, Qinqin Cheng, Tianling Hou, Menglu Han, Goar Smbatyan
Molecular Therapy. 2020-02-05 - 14 citationsLiquid biopsy: from concept to clinical application.Catherine Alix-Panabières, Dario Marchetti, Julie E Lang
Scientific Reports. 2023-12-07 - 129 citationsSelection criteria for genetic assessment of patients with familial melanomaSancy A. Leachman, John A. Carucci, Wendy Kohlmann, Kimberly C. Banks, Maryam M. Asgari
Journal of the American Academy of Dermatology. 2009-10-01
Journal Articles
- RNA-Seq of Circulating Tumor Cells in Stage II–III Breast CancerMichael F Press, Julie E Lang, Annals of Surgical Oncology
Press Mentions
- Major Project to Address ‘Urgent Need’ for Improved Testing of Cancer TherapiesAugust 21st, 2024
- Promise of CTCs in Metastatic Breast Cancer ManagementJanuary 3rd, 2023
- ANGLE Receives FDA Clearance for ParsortixMay 25th, 2022
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: